Moreover, we validated the findings in an AD biomarker-characterised Norwegian cohort consisting of 60 individuals classified as amyloid (A) or tau (T) positive or negative (A-T-, A+T-, or A+T+). The gene discussed is MAPT; the disease is Alzheimer disease.